Compare Merck & Co., Inc. (MRK) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Newmont Corporation — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Newmont Corporation trades at $93.49 (market cap $95.23B). The key difference: Merck & Co., Inc. is far larger — about 3.2× Newmont Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | NEM | |
|---|---|---|
Market Cap | $307.25B | $95.23B |
Sector | Health | Basic Materials |
52-Week High | $129.52 | $131.95 |
52-Week Low | $77.60 | $59.86 |
Enterprise Value | $350.66B | $91.98B |
Dividend Yield | 2.73% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Newmont (NEM) trades at $92.49, up 3.11% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue grew to $22.67B in 2025, net income surged to $7.09B, and cash flow from operations hit $10.33B. Analyst consensus is strongly bullish with a $134.63 price target, though technical indicators show selling pressure near resistance at $92.
The outlook is positive given robust profitability, low P/E of 11.57, and gold price tailwinds, but risks include rising unit costs and production volatility. With 76% of analysts rating it Buy and institutional interest steady, NEM offers value if operational execution holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
